Giovanni Farinea

7PUBLICATIONS
66CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsClinical pharmacology and therapeuticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 26, 2026
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy.

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Dec 31, 2025
Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer.

Giovanni Farinea, Beatriz Antón-Pascual, Juan Luis Catoya Villa

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

|Jan 11, 2024
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer.

Mariangela Calabrese, Isabella Saporita, Fabio Turco

Pageof 2

Frequent Collaborators

4 joint publications

Monica Niger

3 joint publications

Margherita Rimini

3 joint publications

Stephen Lam Chan

3 joint publications

Gerald W Prager